← Back to Search

Other

ETX-018810 for Sciatica

Phase 2
Waitlist Available
Research Sponsored by Eliem Therapeutics (UK) Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to weeks 1, 2, 3 and 4
Awards & highlights

Study Summary

This study is evaluating whether a drug called ETX-018810 may help individuals with chronic back pain.

Eligible Conditions
  • Sciatica

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to weeks 1, 2, 3 and 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to weeks 1, 2, 3 and 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale (PI-NRS)
Secondary outcome measures
Change From Baseline to Week 4 for Worst Pain
Change in BPI - Interference Scale From Baseline to Week 4
Change in the BPI - Pain Scale From Baseline to Week 4
+8 more

Side effects data

From 2022 Phase 2 trial • 167 Patients • NCT04688671
8%
Diarrhoea
2%
Gastrooesophageal reflux disease
2%
Nausea
1%
Sciatica
1%
Myocardial ischaemia
1%
cellulitis
1%
Gastroenteritis astroviral
1%
Respiratory syncytial virus infection
1%
Chronic obstructive pulmonary disease
1%
Cough
1%
Sinus congestion
1%
Vertigo
1%
Constipation
1%
Oesophageal pain
1%
Anaemia
1%
Back pain
1%
Atrial fibrillation
1%
Myalgia
1%
Headache
1%
Pyrexia
1%
Hyperglycaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
ETX-018810
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ETX-018810Experimental Treatment1 Intervention
Drug: ETX-018810 BID for 4 weeks
Group II: PlaceboPlacebo Group1 Intervention
Matching Placebo BID for 4 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ETX-018810
2020
Completed Phase 2
~320

Find a Location

Who is running the clinical trial?

Eliem Therapeutics (UK) Ltd.Lead Sponsor
1 Previous Clinical Trials
167 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain
2021. "Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04778592.
~35 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top